SPRUCE BIOSCIENCES, INC.
For the period ended Jun 30, 2025. Filed Aug 14, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2025 · Filed Aug 14, 2025
SPRB$46.55+9.0%Stored close · as of Nov 6, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Balance Sheets
(in thousands, except share and per share amounts)
| June 30, | December 31, | |
|---|---|---|
| 2025 | 2024 | |
| ASSETS | ||
| Current assets: | ||
| Cash and cash equivalents | $16,387 | $38,753 |
| Prepaid expenses | 1,868 | 3,177 |
| Other current assets | 2,698 | 2,276 |
| Total current assets | 20,953 | 44,206 |
| Right-of-use assets | 803 | 934 |
| Other assets | 64 | 69 |
| Total assets | $21,820 | $45,209 |
| LIABILITIES, REDEEMABLE PREFERRED STOCK, AND STOCKHOLDERS’ EQUITY | ||
| Current liabilities: | ||
| Accounts payable | $807 | $1,295 |
| Accrued expenses and other current liabilities | 6,310 | 12,329 |
| Term loan, current portion | 943 | 1,622 |
| Total current liabilities | 8,060 | 15,246 |
| Lease liabilities, net of current portion | 580 | 736 |
| Term loan, net of current portion | — | 124 |
| Other liabilities | — | 282 |
| Total liabilities | 8,640 | 16,388 |
| Commitments and contingencies | ||
| Series A redeemable preferred stock, $0.0001 par value; 1 share authorized, issued and outstanding as of June 30, 2025; no shares authorized, issued or outstanding as of December 31, 2024 | — | — |
| Stockholders’ equity: | ||
| Preferred stock, $0.0001 par value; 10,000,000 shares authorized and no shares issued or outstanding as of June 30, 2025 and December 31, 2024 | — | — |
| Common stock, $0.0001 par value; 200,000,000 shares authorized as of June 30, 2025 and December 31, 2024; 563,042 shares issued and outstanding as of June 30, 2025 and December 31, 2024 | — | — |
| Additional paid-in capital | 279,556 | 279,089 |
| Accumulated deficit | (266,376) | (250,268) |
| Total stockholders’ equity | 13,180 | 28,821 |
| Total liabilities, redeemable preferred stock, and stockholders’ equity | $21,820 | $45,209 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.